Michael Wang, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the one-year follow-up of ZUMA-2 (NCT02601313), a Phase II, registrational, multicenter study aiming to evaluate KTE-X19 therapy in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL). In patients with a median follow-up of 17.5 months, the objective response rate was 92%, with a complete response (CR) rate of 67%. While common grade adverse events occurred in the majority of the study group, most of them were resolved and no treatment-related secondary cancers were identified. The ZUMA-2 study update highlights the clinical benefit of KTE-X19 therapy in R/R MCL patients, with results showing that most study participants achieved long-term CR with no severe adverse events being reported. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.